

Appendix

The impact of vaccination on COVID-19 outbreaks in the United States

Seyed M. Moghadas,¹ Thomas N. Vilches,² Kevin Zhang,³ Chad R. Wells,⁴ Affan Shoukat,⁴ Burton H. Singer,⁵ Lauren Ancel Meyers,⁷ Kathleen M. Neuzil,⁶ Joanne M. Langley,⁸ Megan C. Fitzpatrick,⁶ Alison P. Galvani⁴

¹ Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada

² Institute of Mathematics, Statistics and Scientific Computing, University of Campinas, Campinas SP, Brazil

³ Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8 Canada

⁴ Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA

⁵ Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA

⁶ Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, MD 21201 USA

⁷ Department of Integrative Biology, The University of Texas at Austin, Austin, TX 78712 USA

⁸ Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and Nova Scotia Health Authority, Halifax, Nova Scotia, B3K 6R8 Canada

This appendix provides further details of model parameterization, projections of attack rates and outcomes with vaccination, as well as sensitivity analyses with varying parameters of vaccine coverage, vaccine efficacy against infection, time interval between the first and second vaccine doses, and results of simulations with and without a reduction of vaccine efficacy in elderly and comorbid individuals.

1. Vaccination

Vaccination campaigns started with distribution of vaccines to healthcare workers (5% of the total population), individuals with comorbidities older than 18 years of age (Table A1), and those aged 65 and older. Healthcare workers included persons employed in ambulatory care, hospitals, nursing homes, and long-term care facilities (1). Comorbidities considered in vaccine prioritization included cardiovascular disease, diabetes, asthma, chronic obstructive pulmonary disease, hypertension, and cancer (2). On each day, 30 doses of vaccine per 10,000 population were distributed, with a second dose being offered after the specified time interval (either 21 or 28 days after the first dose). Second priority groups included individuals aged 18-64, and vaccines were distributed randomly to reach the overall coverage of 40% for both vaccine doses (or the specified coverage in the sensitivity analyses).

2. Model parameters

Table A1. Percentage of population in different age groups with and without comorbidities.

Condition	0-4	5-19	20-49	50-64	65+	All age groups
With comorbidity	5%	10%	28%	55%	78%	37%
Without comorbidity	95%	90%	72%	45%	22%	63%
Fraction of total population	5.9%	18.9%	39.6%	18.9%	16.6%	100%

The number of daily contacts for each agent was sampled from an age-specific negative binomial distribution and contacts were distributed among different age groups based on a contact matrix (Table A2) (3). For reduced contacts due to interventions (i.e., self-isolation), we used estimates of contacts derived from a recent study quantifying the impact of physical distancing during the COVID-19 lockdown in the UK (4). Measures of lockdown included school closure, quarantine and isolation of cases, and physical distancing in workplaces. The reduction of daily contacts for self-isolated individuals was at least 70% in different age groups. The overall effect of contact patterns was implicitly accounted for in the model calibration to the effective reproduction number.

Table A2. Mixing patterns and the daily number of contacts derived from empirical observations. Daily numbers of contacts were sampled from negative binomial distributions for different scenarios.

Age group	Proportion of contacts between age groups					Number of daily contacts without self-isolation Mean (SD) Ref: (3)	Number of daily contacts for self-isolated individuals Mean (SD) Ref: (4)
	0-4	5-19	20-49	50-65	65+		
0-4	0.2287	0.1839	0.4219	0.1116	0.0539	10.21 (7.65)	2.86 (2.14)

5-19	0.0276	0.5964	0.2878	0.0591	0.0291	16.793 (11.7201)	4.70 (3.28)
20-49	0.0376	0.1454	0.6253	0.1423	0.0494	13.795 (10.5045)	3.86 (2.95)
50-65	0.0242	0.1094	0.4867	0.2723	0.1074	11.2669 (9.5935)	3.15 (2.66)
65+	0.0207	0.1083	0.4071	0.2193	0.2446	8.0027 (6.9638)	2.24 (1.95)

Table A3. Distribution of the levels of pre-existing immunity in different age groups before vaccine implementation.

Pre-existing immunity	0-4	5-19	20-49	50-64	65-79	80+
5%	1.5%	7.9%	6.6%	3.6%	0.5%	0.9%
10%	5.4%	14.8%	12.4%	7.5%	3.3%	3.5%
20%	11.9%	28.2%	24.3%	16.0%	8.0%	8.1%

Table A4. Vaccination coverage of different age groups.

Age group	0-17	18-49	50-64	65-79	80+
Vaccination coverage	0%	48%	48%	70%	70%

3. Estimates of attack rates, hospitalizations, and deaths

Estimates in this section correspond to the results presented in the main text with 40% vaccination coverage, and a 21-day time interval between the two vaccine doses. Vaccine

efficacy against infection was 50% lower than the efficacy against disease after each dose, and this efficacy was reduced by 10-50% in vaccinated elderly and comorbid individuals.

Table A5. Projected age-specific and overall attack rates per 10,000 population without vaccination and with 40% vaccination coverage over 300 days, corresponding to Figures 2 and 3 of the main text.

Age group	0-4	5-19	20-49	50-64	65-79	80+	All
Pre-existing immunity	Mean projected attack rate % (95% CrI) without vaccination						
5%	4.1 3.8 - 4.4	11.7 10.9 - 12.7	10.0 9.3 - 10.7	6.1 5.7 - 6.6	2.8 2.6 - 3.0	2.8 2.6 - 3.1	8.0 7.4 - 8.6
10%	4.7 4.4 - 5.0	12.6 11.8 - 13.3	11.2 10.5 - 11.8	7.0 6.6 - 7.4	3.3 3.1 - 3.5	3.3 3.1 - 3.5	9.0 8.4 - 9.5
20%	3.5 3.3 - 3.7	8.5 8.0 - 8.9	7.9 7.5 - 8.3	5.3 4.9 - 5.6	2.6 2.4 - 2.8	2.6 2.4 - 2.7	6.4 6.0 - 6.7
	Mean projected attack rate % (95% CrI) with vaccination						
5%	2.0 1.8 - 2.2	6.1 5.6 - 6.5	4.5 4.1 - 4.9	2.5 2.3 - 2.8	1.1 1.0 - 1.2	1.1 1.0 - 1.2	3.7 3.4 - 4.0
10%	2.4 2.3 - 2.6	7.3 6.8 - 7.9	5.6 5.2 - 6.0	3.3 3.1 - 3.5	1.4 1.3 - 1.5	1.4 1.3 - 1.5	4.6 4.3 - 5.0
20%	1.9 1.7 - 2.0	4.8 4.5 - 5.2	4.1 3.8 - 4.3	2.6 2.4 - 2.7	1.2 1.1 - 1.2	1.2 1.1 - 1.3	3.3 3.1 - 3.5

Table A6. Projected age-specific and overall non-ICU hospitalizations per 10,000 population without vaccination and with 40% vaccination coverage over 300 days, corresponding to Figure 4 of the main text.

Age group	0-4	5-19	20-49	50-64	65-79	80+	All
Pre-existing immunity	Mean projected total non-ICU hospitalizations (95% CrI) without vaccination						
5%	0.1 0.1 - 0.1	1.2 1.1 - 1.3	4.7 4.3 - 5.0	5.4 5.0 - 5.8	2.6 2.4 - 2.9	3.8 3.5 - 4.2	17.8 16.5 - 19.1
10%	0.1 0.1 - 0.1	1.3 1.2 - 1.4	5.3 4.9 - 5.6	6.3 5.9 - 6.7	3.0 2.8 - 3.3	4.4 4.1 - 4.7	20.3 18.9 - 21.6
20%	0.1 0.0 - 0.1	0.8 0.8 - 0.9	3.7 3.5 - 3.9	4.9 4.6 - 5.3	2.4 2.3 - 2.6	3.4 3.2 - 3.6	15.3 14.4 - 16.3

	Mean projected total non-ICU hospitalizations (95% CrI) with vaccination						
5%	0.0 0.0 - 0.1	0.6 0.5 - 0.7	1.8 1.6 - 1.9	1.9 1.7 - 2.1	0.7 0.6 - 0.8	1.0 0.9 - 1.1	6.0 5.5 - 6.5
10%	0.0 0.0 - 0.0	0.7 0.6 - 0.8	2.2 2.1 - 2.4	2.5 2.3 - 2.7	1.0 0.9 - 1.1	1.4 1.3 - 1.5	7.9 7.3 - 8.5
20%	0.0 0.0 - 0.0	0.5 0.4 - 0.6	1.7 1.5 - 1.8	2.3 2.2 - 2.5	0.9 0.8 - 1.0	1.3 1.2 - 1.4	6.6 6.2 - 7.1

Table A7. Projected age-specific and overall ICU hospitalizations per 10,000 population without vaccination and with 40% vaccination coverage over 300 days, corresponding to Figure 4 of the main text.

Age group	0-4	5-19	20-49	50-64	65-79	80+	All
Pre-existing immunity	Mean projected total ICU hospitalizations (95% CrI) without vaccination						
5%	0.0 0.0 - 0.0	0.5 0.4 - 0.5	2.1 2.0 - 2.3	2.5 2.3 - 2.7	1.3 1.2 - 1.5	1.7 1.6 - 1.9	8.1 7.5 - 8.7
10%	0.0 0.0 - 0.0	0.5 0.4 - 0.5	2.2 2.0 - 2.3	3.0 2.8 - 3.2	1.5 1.4 - 1.6	2.2 2.0 - 2.4	9.3 8.7 - 10.0
20%	0.0 0.0 - 0.0	0.3 0.3 - 0.3	1.6 1.5 - 1.7	2.3 2.1 - 2.5	1.2 1.1 - 1.3	1.6 1.5 - 1.7	7.0 6.5 - 7.4
	Mean projected total ICU hospitalizations (95% CrI) with vaccination						
5%	0.0 0.0 - 0.0	0.2 0.2 - 0.2	0.8 0.7 - 0.8	0.8 0.8 - 0.9	0.3 0.3 - 0.4	0.5 0.4 - 0.6	2.7 2.4 - 3.0
10%	0.0 0.0 - 0.0	0.3 0.3 - 0.3	0.9 0.9 - 1.0	1.1 1.0 - 1.2	0.5 0.4 - 0.5	0.6 0.6 - 0.7	3.4 3.1 - 3.7
20%	0.0 0.0 - 0.0	0.2 0.2 - 0.2	0.7 0.6 - 0.8	1.1 1.0 - 1.2	0.5 0.4 - 0.5	0.6 0.5 - 0.7	3.0 2.8 - 3.2

Table A8. Projected age-specific and overall deaths per 10,000 population without vaccination and with 40% vaccination coverage over 300 days, corresponding to Figure 4 of the main text.

Age group	0-4	5-19	20-49	50-64	65-79	80+	All
Pre-existing immunity	Mean projected total deaths (95% CrI) without vaccination						

5%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.2 0.1 - 0.2	0.3 0.3 - 0.3	0.4 0.3 - 0.4	1.1 1.0 - 1.2	2.0 1.8 - 2.2
10%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.2 0.1 - 0.2	0.4 0.4 - 0.4	0.4 0.3 - 0.4	1.3 1.2 - 1.4	2.2 2.1 - 2.4
20%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.1 0.1 - 0.2	0.3 0.2 - 0.3	0.4 0.3 - 0.4	1.0 0.9 - 1.0	1.8 1.6 - 1.9
	Mean projected total deaths (95% CrI) with vaccination						
5%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.1 0.1 - 0.1	0.1 0.1 - 0.2	0.1 0.1 - 0.1	0.3 0.2 - 0.3	0.6 0.5 - 0.7
10%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.1 0.1 - 0.1	0.2 0.1 - 0.2	0.1 0.1 - 0.2	0.4 0.3 - 0.4	0.8 0.7 - 0.8
20%	0.0 0.0 - 0.0	0.0 0.0 - 0.0	0.1 0.1 - 0.1	0.1 0.1 - 0.2	0.1 0.1 - 0.2	0.4 0.3 - 0.4	0.7 0.7 - 0.8

References

1. Kaiser Family Foundation. Total Health Care Employment [Internet]. KFF. 2019 [cited 2020 Dec 30]. Available from: <https://www.kff.org/other/state-indicator/total-health-care-employment/>
2. Adams ML, Katz DL, Grandpre J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States - Volume 26, Number 8—August 2020. Emerg Infect Dis [Internet]. [cited 2020 Dec 27]; Available from: https://wwwnc.cdc.gov/eid/article/26/8/20-0679_article
3. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. Riley S, editor. PLoS Med [Internet]. 2008 Mar 25 [cited 2020 May 22];5(3):e74. Available from: <https://dx.plos.org/10.1371/journal.pmed.0050074>
4. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, CMMID COVID-19 working group, Klepac P, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Med [Internet]. 2020 Dec [cited 2020 Aug 9];18(1):124. Available from: <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01597-8>

4. Sensitivity analyses for vaccination scenarios with different coverages and protection efficacies against infection. Time interval between the two vaccine doses is 21 days.

Part 1: Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.




Figure A1. Projected daily incidence of COVID-19 per 10,000 population with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.




Figure A2. Projected attack rates with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.

Part 2: There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.




Figure A3. Projected daily incidence of COVID-19 per 10,000 population with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.




Figure A4. Projected attack rates with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.

Part 3: Non-ICU hospitalizations, ICU hospitalizations, and deaths




Figure A5. Projected total number of non-ICU hospitalizations per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.




Figure A6. Projected total number of ICU hospitalizations per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.




Figure A7. Projected total number of deaths per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.

5. Sensitivity analyses for vaccination scenarios with different coverages and protection efficacies against infection. Time interval between the two vaccine doses is 28 days.

Part 1: Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.




Figure A8. Projected daily incidence of COVID-19 per 10,000 population with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.





Figure A9. Projected attack rates with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Vaccine efficacy was reduced by 10-50% among vaccinated elderly and comorbid individuals.

Part 2: There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.

Figure A10. Projected daily incid



ence of COVID-19 per 10,000 population with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.




Figure A11. Projected attack rates with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60%. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). There was no reduction of vaccine efficacy among vaccinated elderly and comorbid individuals.

Part 3: Non-ICU hospitalizations, ICU hospitalizations, and deaths




Figure A12. Projected total number of non-ICU hospitalizations per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.




Figure A13. Projected total number of ICU hospitalizations per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.




Figure 14. Projected total number of deaths per 10,000 populations with 5% (A,D,G), 10% (B,E,H), and 20% (C,F,I) pre-existing immunity and different vaccination coverage in the range 10-60% over 300 days. The protection efficacy of vaccines against infection is 0% (A,B,C), 50% lower than the efficacy against disease (D,E,F), and the same as efficacy against disease (G,H,I). Colored bars with vaccination correspond to scenarios with and without reduction of vaccine efficacy in comorbid individuals and the elderly.